Table 2.

Risk stratification for patients with diabetes

Adapted IDF-DAR risk stratification table, reproduced with permission from the South East London Area Prescribing Committee [97]

CKD Chronic kidney disease, DKA diabetic ketoacidosis, DPP-4 dipeptidyl peptidase-4, GDM gestational diabetes mellitus, GLP-1 RA glucagon-like peptide-1 receptor agonist, MDI multiple dose insulin, MTF metformin, SGLT-2 sodium-glucose co-transporter 2, SMBG self-monitoring of blood glucose, SU sulfonylurea, T1DM Type 1 diabetes mellitus, T2DM Type 2 diabetes mellitus

^aIn all categories, people with diabetes should be advised to follow medical opinion due to probability of harm. The decision to fast is a personal decision for the person with diabetes, who should be supported by the healthcare professional (HCP) to achieve best possible outcomes

^bHypoglycaemia that is not due to accidental error in insulin dose

^cThe expected level of glycaemic control is to be agreed upon between HCP and patient according to a multitude of factors. Glycated haemoglobin (HbA1c) > 75 mmol/mol for >12 months should be used as an indicator of poor control

^*Risk upgraded in light of COVID-19 pandemic